SOD1 and amyotrophic lateral sclerosis: SOD1 knockdown by tofersen and other SOD1 protein‐reducing agents that are non‐allele specific will affect all areas of the CNS in a similar manner, including those which are less impaired during ALS disease progression, given a similar distribution throughout the CNS after intrathecal injection of the drug.